## Antoni Gual

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5808410/publications.pdf

Version: 2024-02-01

200 papers

7,157 citations

38 h-index 69250

g-index

219 all docs 219 docs citations

times ranked

219

6478 citing authors

#	Article	IF	CITATIONS
1	Development of community strategies supporting brief alcohol advice in three Latin American countries: a protocol. Health Promotion International, 2023, 38, .	1.8	4
2	Primary care provider expectations of addiction services and patients in Spain. Family Practice, 2022, 39, 269-274.	1.9	6
3	The International Cannabis Toolkit (iCannToolkit): a multidisciplinary expert consensus on minimum standards for measuring cannabis use. Addiction, 2022, 117, 1510-1517.	3.3	44
4	Killing me softly: Alcohol addiction today. European Neuropsychopharmacology, 2022, 57, 30-32.	0.7	1
5	Changes in alcohol use during the <scp>COVID</scp> â€19 pandemic in Europe: A metaâ€analysis of observational studies. Drug and Alcohol Review, 2022, 41, 918-931.	2.1	49
6	The iCannToolkit: a tool to embrace measurement of medicinal and nonâ€medicinal cannabis use across licit, illicit and crossâ€cultural settings. Addiction, 2022, , .	3.3	3
7	Training primary health care providers in Colombia, Mexico and Peru to increase alcohol screening: Mixed-methods process evaluation of implementation strategy. Implementation Research and Practice, 2022, 3, 263348952211126.	1.9	2
8	Sodium oxybate for the maintenance of abstinence in alcohol-dependent patients: An international, multicenter, randomized, double-blind, placebo-controlled trial. Journal of Psychopharmacology, 2022, 36, 1136-1145.	4.0	5
9	Attentional Bias, Alcohol Craving, and Anxiety Implications of the Virtual Reality Cue-Exposure Therapy in Severe Alcohol Use Disorder: A Case Report. Frontiers in Psychology, 2021, 12, 543586.	2.1	11
10	Factors Affecting Quality of Life in Liver Transplant Candidates: An Observational Study. Transplantology, 2021, 2, 64-74.	0.6	0
11	Mid and long-term effects of a SBIRT program for at-risk drinkers attending to an emergency department. Follow-up results from a randomized controlled trial European Journal of Emergency Medicine, 2021, 28, 373-379.	1.1	6
12	Abstinence Among Alcohol Use Disorder Patients During the COVIDâ€19 Pandemic: Insights From Spain. Alcoholism: Clinical and Experimental Research, 2021, 45, 802-807.	2.4	19
13	Factors Associated with Primary Health Care Providers' Alcohol Screening Behavior in Colombia, Mexico and Peru. Substance Abuse, 2021, 42, 1007-1015.	2.3	4
14	The right to smoke and the right to smoke-free surroundings: international comparison of smoke-free psychiatric clinic implementation experiences. BJPsych Open, 2021, 7, e81.	0.7	4
15	Supporting Future Cannabis Policy – Developing a Standard Joint Unit: A Brief Back-Casting Exercise. Frontiers in Psychiatry, 2021, 12, 675033.	2.6	4
16	Conducting a multiâ€country online alcohol survey in the time of the COVIDâ€19 pandemic: Opportunities and challenges. International Journal of Methods in Psychiatric Research, 2021, 30, e1875.	2.1	4
17	Determinants of Cue-Elicited Alcohol Craving and Perceived Realism in Virtual Reality Environments among Patients with Alcohol Use Disorder. Journal of Clinical Medicine, 2021, 10, 2241.	2.4	4
18	Motivational Interviewing for Cannabis Use Disorders: A Systematic Review and Meta-Analysis. European Addiction Research, 2021, 27, 413-427.	2.4	24

#	Article	IF	CITATIONS
19	Alcohol consumption during the COVIDâ€19 pandemic in Europe: a largeâ€scale crossâ€sectional study in 21 countries. Addiction, 2021, 116, 3369-3380.	3.3	108
20	Direct Alcohol Biomarkers Prediction Capacity on Relapse and Mortality in Liver Transplantation Candidates: A Follow-Up Study. Transplantology, 2021, 2, 246-252.	0.6	0
21	Early, Chronic, and Acute Cannabis Exposure and Their Relationship With Cognitive and Behavioral Harms. Frontiers in Psychiatry, 2021, 12, 643556.	2.6	3
22	Baseline severity and the prediction of placebo response in clinical trials for alcohol dependence: A metaâ€regression analysis to develop an enrichment strategy. Alcoholism: Clinical and Experimental Research, 2021, 45, 1722-1734.	2.4	12
23	Primary care-based screening and management of depression amongst heavy drinking patients: Interim secondary outcomes of a three-country quasi-experimental study in Latin America. PLoS ONE, 2021, 16, e0255594.	2.5	5
24	Treating alcohol dependence with an abuse and misuse deterrent formulation of sodium oxybate: Results of a randomised, double-blind, placebo-controlled study. European Neuropsychopharmacology, 2021, 52, 18-30.	0.7	13
25	Standard units for cannabis dose: Why is it important to standardize cannabis dose for drug policy and how can we enhance its place on the public health agenda?. International Journal of Drug Policy, 2021, 97, 103350.	3.3	5
26	A randomized controlled non-inferiority trial of primary care-based facilitated access to an alcohol reduction website (EFAR Spain). Internet Interventions, 2021, 26, 100446.	2.7	4
27	Perceived appropriateness of alcohol screening and brief advice programmes in Colombia, Mexico and Peru and barriers to their implementation in primary health care – a cross-sectional survey. Primary Health Care Research and Development, 2021, 22, e4.	1.2	3
28	Relaci $\tilde{A}^3$ n entre las motivaciones para consumir y el consumo problem $\tilde{A}_I$ tico de cannabis. Revista De Psicologia De La Salud, 2021, 33, 31.	0.5	14
29	Impact of Training and Municipal Support on Primary Health Care–Based Measurement of Alcohol Consumption in Three Latin American Countries: 5-Month Outcome Results of the Quasi-experimental Randomized SCALA Trial. Journal of General Internal Medicine, 2021, 36, 2663-2671.	2.6	10
30	OUP accepted manuscript. Alcohol and Alcoholism, 2021, , .	1.6	1
31	Biological State Marker for Alcohol Consumption. , 2021, , 595-617.		0
32	Digital brief interventions for risky drinkers are not the panacea: A pilot study exploring barriers for its implementation according to professionals' perceptions. Health Informatics Journal, 2020, 26, 925-933.	2.1	1
33	Safety of nalmefene for the treatment of alcohol use disorder: an update. Expert Opinion on Drug Safety, 2020, 19, 9-17.	2.4	3
34	Phosphatidylethanol for Monitoring Alcohol Use in Liver Transplant Candidates: An Observational Study. Journal of Clinical Medicine, 2020, 9, 3060.	2.4	11
35	Alcohol Control Policy in Europe: Overview and Exemplary Countries. International Journal of Environmental Research and Public Health, 2020, 17, 8162.	2.6	19
36	"The post-COVID era― challenges in the treatment of substance use disorder (SUD) after the pandemic. BMC Medicine, 2020, 18, 241.	5 <b>.</b> 5	44

#	Article	IF	CITATIONS
37	Implementing primary healthcare-based measurement, advice and treatment for heavy drinking and comorbid depression at the municipal level in three Latin American countries: final protocol for a quasiexperimental study (SCALA study). BMJ Open, 2020, 10, e038226.	1.9	16
38	Predictors of Changes in Alcohol Craving Levels during a Virtual Reality Cue Exposure Treatment among Patients with Alcohol Use Disorder. Journal of Clinical Medicine, 2020, 9, 3018.	2.4	22
39	A systematic review of treatments for alcohol-related cognitive impairment: lessons from the past and gaps for future interventions. Psychological Medicine, 2020, 50, 2113-2127.	4.5	15
40	Active Smoking Before Liver Transplantation in Patients with Alcohol Use Disorder: Risk Factors and Outcomes. Journal of Clinical Medicine, 2020, 9, 2710.	2.4	4
41	Papel de la detección regular de sustancias en orina en pacientes en valoración pre-transplante hepático por hepatopatAa alcohólica. Revista De Psicologia De La Salud, 2020, 32, 243.	0.5	1
42	Remote Monitoring Telemedicine (REMOTE) Platform for Patients With Anxiety Symptoms and Alcohol Use Disorder: Protocol for a Case-Control Study. JMIR Research Protocols, 2020, 9, e16964.	1.0	6
43	DSM-5 en pacientes que solicitan el primer tratamiento del trastorno por uso de alcohol. Diferencias de sexo en el estudio multicéntrico CohRTA. Revista De Psicologia De La Salud, 2020, 32, 136.	0.5	6
44	e-INEBRIA Special Interest Group Roadmap for Best Practices for Research on Brief Digital Interventions for Problematic Alcohol and Illicit Drug Use. Journal of Medical Internet Research, 2020, 22, e20368.	4.3	7
45	Cue-Elicited Anxiety and Alcohol Craving as Indicators of the Validity of ALCO-VR Software: A Virtual Reality Study. Journal of Clinical Medicine, 2019, 8, 1153.	2.4	19
46	<scp>ICD</scp> â€11 for Alcohol Use Disorders: Not a Convincing Answer to the Challenges. Alcoholism: Clinical and Experimental Research, 2019, 43, 2296-2300.	2.4	9
47	Motor Adaptation Impairment in Chronic Cannabis Users Assessed by a Visuomotor Rotation Task. Journal of Clinical Medicine, 2019, 8, 1049.	2.4	9
48	Comments from the Editors on the Special Issue "Assessment and Treatment of Addictions: New Tools for Old Problems― Journal of Clinical Medicine, 2019, 8, 1717.	2.4	0
49	Call for Action: Benzodiazepine Prescription Prevalence Analysis Shows Off-Label Prescription in One in Eleven Citizens. European Addiction Research, 2019, 25, 320-329.	2.4	11
50	What Do Real Alcohol Outpatients Expect about Alcohol Transdermal Sensors?. Journal of Clinical Medicine, 2019, 8, 795.	2.4	3
51	The More You Take It, the Better It Works: Six-Month Results of a Nalmefene Phase-IV Trial. Journal of Clinical Medicine, 2019, 8, 471.	2.4	3
52	Factors affecting engagement of primary health care professionals and their patients in facilitated access to online alcohol screening and brief intervention. International Journal of Medical Informatics, 2019, 127, 95-101.	3.3	1
53	Why Less Is Always More in the Treatment of Alcohol Use Disorders. JAMA Psychiatry, 2019, 76, 359.	11.0	11
54	Prediction of Alcohol Relapse Among Liver Transplant Candidates With Less Than 6 Months of Abstinence Using the Highâ∈Risk Alcoholism Relapse Score. Liver Transplantation, 2019, 25, 1142-1154.	2.4	20

#	Article	IF	Citations
55	Identifying Triggers of Alcohol Craving to Develop Effective Virtual Environments for Cue Exposure Therapy. Frontiers in Psychology, 2019, 10, 74.	2.1	26
56	Cerebellar alterations in cannabis users: A systematic review. Addiction Biology, 2019, 24, 1121-1137.	2.6	35
57	Treatment retention in a specialized alcohol programme after an episode of alcoholic hepatitis: Impact on alcohol relapse. Journal of Psychosomatic Research, 2019, 116, 75-82.	2.6	13
58	Psychiatric Comorbidity in Treatment-Seeking Alcohol Dependence Patients With and Without ADHD. Journal of Attention Disorders, 2019, 23, 1497-1504.	2.6	24
59	Una comparación entre los estudios de fase 3 y un estudio de fase 4 de nalmefeno en el trastorno por uso de alcohol. ¿Existen diferencias?. Revista De Psicologia De La Salud, 2019, 31, 284.	0.5	0
60	Reply to Braillon et al.:ÂNalmefene Phase IV Study: A Seeding Flying in the Face of Evidence?. Clinical Drug Investigation, 2018, 38, 387-388.	2.2	0
61	EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. Journal of Hepatology, 2018, 69, 154-181.	3.7	591
62	Effectiveness of a Specialized Brief Intervention for Atâ€risk Drinkers in an Emergency Department: Shortâ€term Results of a Randomized Controlled Trial. Academic Emergency Medicine, 2018, 25, 517-525.	1.8	22
63	Filling the gap between lab and clinical impact: An open randomized diagnostic trial comparing urinary ethylglucuronide and ethanol in alcohol dependent outpatients. Drug and Alcohol Dependence, 2018, 183, 225-230.	3.2	4
64	Alcohol, tobacco and health care costs: a population-wide cohort study (n = 606 947 patients) of current drinkers based on medical and administrative health records from Catalonia. European Journal of Public Health, 2018, 28, 674-680.	0.3	10
65	Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results. Clinical Drug Investigation, 2018, 38, 147-155.	2.2	15
66	Risky Alcohol Use: The Impact on Health Service Use. European Addiction Research, 2018, 24, 234-244.	2.4	18
67	New Alcohol Biomarkers. New challenges. Alcohol and Alcoholism, 2018, 53, 762-763.	1.6	9
68	Barriers to implement screening for alcohol consumption in Spanish hypertensive patients. Family Practice, 2018, 35, 295-301.	1.9	5
69	Quantitative Criteria to Screen for Cannabis Use Disorder. European Addiction Research, 2018, 24, 109-117.	2.4	6
70	Efficacy and safety of sodium oxybate in alcoholâ€dependent patients with a very high drinking risk level. Addiction Biology, 2018, 23, 969-986.	2.6	59
71	Reducing the health risks derived from exposure to addictive substances. Current Opinion in Psychiatry, 2018, 31, 333-341.	6.3	8
72	A Survey on the Medical Use of Cannabis in Europe: A Position Paper. European Addiction Research, 2018, 24, 201-205.	2.4	19

#	Article	IF	Citations
73	Alcoholic liver disease. Nature Reviews Disease Primers, 2018, 4, 16.	30.5	660
74	Optimizing the delivery of interventions for harmful alcohol use in primary healthcare. Current Opinion in Psychiatry, 2018, 31, 324-332.	6.3	8
75	Reducción de la mortalidad mediante una mejor detección de la hipertensión y los problemas con el alcohol en atención primaria de salud en España. Revista De Psicologia De La Salud, 2018, 30, 9.	0.5	7
76	Terapia de rehabilitaci $\tilde{A}^3$ n cognitiva en pacientes con trastorno por consumo de alcohol y trastorno neurocognitivo. Estudio piloto Revista De Psicologia De La Salud, 2018, 30, 93.	0.5	5
77	Pacientes con trastorno por uso de alcohol: resultados iniciales de un registro multicéntrico en la Red de Trastornos Adictivos-RTA. Estudio CohRTA. Revista De Psicologia De La Salud, 2018, 30, 292.	0.5	1
78	Rol de la calidad de vida en el consumo de riesgo de alcohol: ¿debe ser una variable más relevante en cualquier investigación en este campo. Revista De Psicologia De La Salud, 2018, 30, 301.	0.5	0
79	Self-management and Shared Decision-Making in Alcohol Dependence via a Mobile App: a Pilot Study. International Journal of Behavioral Medicine, 2017, 24, 722-727.	1.7	29
80	Risky Drinkers Underestimate their Own Alcohol Consumption. Alcohol and Alcoholism, 2017, 52, 516-517.	1.6	12
81	The Standard Joint Unit. Drug and Alcohol Dependence, 2017, 176, 109-116.	3.2	43
82	Barriers to Alcohol Screening Among Hypertensive Patients and the Role of Stigma: Lessons for the Implementation of Screening and Brief Interventions in European Primary Care Settings. Alcohol and Alcoholism, 2017, 52, 572-579.	1.6	21
83	Social costs of illegal drugs, alcohol and tobacco in the European Union: A systematic review. Drug and Alcohol Review, 2017, 36, 578-588.	2.1	37
84	Delivery of Brief Interventions for Heavy Drinking in Primary Care: Outcomes of the ODHIN 5-Country Cluster Randomized Trial. Annals of Family Medicine, 2017, 15, 335-340.	1.9	31
85	Patients' Knowledge and Attitudes Towards Regular Alcohol Urine Screening: A Survey Study. Journal of Addiction Medicine, 2017, 11, 300-307.	2.6	3
86	Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: Prediction and impact on longâ€ŧerm survival. Hepatology, 2017, 66, 1842-1853.	7.3	119
87	One Year Clinical Correlates of EtG Positive Urine Screening in Alcohol-Dependent Patients: A Survival Analysis. Alcohol and Alcoholism, 2017, 52, 460-465.	1.6	9
88	Rethinking alcohol interventions in health care: a thematic meeting of the International Network on Brief Interventions for Alcohol & Drugs (INEBRIA). Addiction Science & Drugs (INEBRIA). Addiction Science & Drugs (Inical Practice, 2017, 12, 14.	2.6	48
89	Attitudes and Learning through Practice Are Key to Delivering Brief Interventions for Heavy Drinking in Primary Health Care: Analyses from the ODHIN Five Country Cluster Randomized Factorial Trial. International Journal of Environmental Research and Public Health, 2017, 14, 121.	2.6	25
90	Towards new recommendations to reduce the burden of alcohol-induced hypertension in the European Union. BMC Medicine, 2017, 15, 173.	5.5	24

#	Article	IF	CITATIONS
91	Reframing the science and policy of nicotine, illegal drugs and alcohol $\hat{a} \in \text{``conclusions}$ of the ALICE RAP Project. F1000Research, 2017, 6, 289.	1.6	11
92	Scaling-up primary health care-based prevention and management of alcohol use disorder at the municipal level in middle-income countries in Latin America: Background and pre-protocol for a three-country quasi-experimental study. F1000Research, 2017, 6, 311.	1.6	9
93	Estableciendo la unidad de porro estándar: estudio piloto. Revista De Psicologia De La Salud, 2017, 29, 227.	0.5	11
94	Scaling-up primary health care-based prevention and management of heavy drinking at the municipal level in middle-income countries in Latin America: Background and protocol for a three-country quasi-experimental study. F1000Research, 2017, 6, 311.	1.6	9
95	European Addiction Research Becomes the Official Journal of the European Federation of Addiction Societies. European Addiction Research, 2016, 22, I-II.	2.4	1
96	Patient-centered care interventions for the management of alcohol use disorders: a systematic review of randomized controlled trials. Patient Preference and Adherence, 2016, Volume 10, 1823-1845.	1.8	20
97	Editorial: Brief Interventions for Risky Drinkers. Frontiers in Psychiatry, 2016, 7, 42.	2.6	3
98	Improving the delivery of brief interventions for heavy drinking in primary health care: outcome results of the Optimizing Delivery of Health Care Intervention (ODHIN) five-country cluster randomized factorial trial. Addiction, 2016, 111, 1935-1945.	3.3	73
99	Nalmefene is effective at reducing alcohol seeking, treating alcoholâ€cocaine interactions and reducing alcoholâ€induced histone deacetylases gene expression in blood. British Journal of Pharmacology, 2016, 173, 2490-2505.	5.4	17
100	The role of alcohol in the management of hypertension in patients in European primary health care practices $\hat{a} \in \hat{a}$ a survey in the largest European Union countries. BMC Family Practice, 2016, 17, 130.	2.9	24
101	Early screening and brief intervention in alcohol misuse to improve the treatment of hypertension in primary care. Medicina ClÃnica (English Edition), 2016, 146, 81-85.	0.2	1
102	Alcohol consumption in upper aerodigestive tract cancer: Role of head and neck surgeons' recommendations. Alcohol, 2016, 51, 51-56.	1.7	7
103	Treatment of alcohol use disorders in patients with alcoholic liver disease. Journal of Hepatology, 2016, 65, 618-630.	3.7	156
104	Aspectos éticos en relación con un compañero con problemas de adicción a sustancias. FMC Formacion Medica Continuada En Atencion Primaria, 2016, 23, 315-317.	0.0	0
105	Alcohol Consumption and Inpatient Health Service Utilization in a Cohort of Patients With Alcohol Dependence After 20 Years of Follow-up. Alcohol and Alcoholism, 2016, 52, 227-233.	1.6	12
106	Back to basics. Addiction, 2016, 111, 1529-1530.	3.3	1
107	Deconstructing myths, building alliances: a networking model to enhance tobacco control in hospital mental health settings. Gaceta Sanitaria, 2016, 30, 389-392.	1.5	4
108	Reply to "Treatment of alcohol use disorders in patients with liver disease― Journal of Hepatology, 2016, 65, 1271.	3.7	1

#	Article	IF	CITATIONS
109	Definitions of Risky and Problematic Cannabis Use: A Systematic Review. Substance Use and Misuse, 2016, 51, 1760-1770.	1.4	42
110	Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy. European Neuropsychopharmacology, 2016, 26, 1941-1949.	0.7	77
111	Implementing referral to an electronic alcohol brief advice website in primary healthcare: results from the ODHIN implementation trial. BMJ Open, 2016, 6, e010271.	1.9	14
112	Urine Ethyl Glucuronide Unraveling the Reality of Abstinence Monitoring in a Routine Outpatient Setting: A Cross-Sectional Comparison with Ethanol, Self Report and Clinical Judgment. European Addiction Research, 2016, 22, 243-248.	2.4	16
113	Policy implications of marked reversals of population life expectancy caused by substance use. BMC Medicine, 2016, 14, 42.	5.5	22
114	Alcohol use disorders in Europe: A comparison of general population and primary health care prevalence rates. Journal of Substance Use, 2016, 21, 478-484.	0.7	24
115	Alcohol Use Disorders in Primary Health Care: What Do We Know and Where Do We Go?. Alcohol and Alcoholism, 2016, 51, 422-427.	1.6	124
116	Alcohol Dependence, Co-occurring Conditions and Attributable Burden. Alcohol and Alcoholism, 2016, 51, 201-209.	1.6	50
117	El alcoholismo y su abordaje desde una perspectiva ciudadana. Revista De Psicologia De La Salud, 2016, 28, 163.	0.5	7
118	Development, Validation, and Implementation of an Innovative Mobile App for Alcohol Dependence Management: Protocol for the SIDEAL Trial. JMIR Research Protocols, 2016, 5, e27.	1.0	7
119	Alcohol in Primary Care. Differential characteristics between alcohol-dependent patients who are receiving or not receiving treatment. Revista De Psicologia De La Salud, 2016, 28, 116-22.	0.5	2
120	Rozpoznawanie uzależnienia od alkoholu przez lekarzy podstawowej opieki zdrowotnej: polskie wyniki europejskiego projektu badawczego Alcoholism in Primary Care. Alkoholizm I Narkomania, 2015, 28, 163-171.	0.1	1
121	Impact of primary healthcare providers' initial role security and therapeutic commitment on implementing brief interventions in managing risky alcohol consumption: a cluster randomised factorial trial. Implementation Science, 2015, 11, 96.	6.9	8
122	People with Alcohol Use Disorders in Specialized Care in Eight Different European Countries. Alcohol and Alcoholism, 2015, 50, 310-318.	1.6	45
123	General Practitioners Recognizing Alcohol Dependence: A Large Cross-Sectional Study in 6 European Countries. Annals of Family Medicine, 2015, 13, 28-32.	1.9	80
124	Professional's Attitudes Do Not Influence Screening and Brief Interventions Rates for Hazardous and Harmful Drinkers: Results from ODHIN Study. Alcohol and Alcoholism, 2015, 50, 430-437.	1.6	32
125	Secondhand smoke in psychiatric units: patient and staff misperceptions. Tobacco Control, 2015, 24, e212-e220.	3.2	7
126	Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme. Expert Opinion on Drug Safety, 2015, 14, 495-504.	2.4	18

#	Article	IF	CITATIONS
127	Association of second-hand smoke exposure at home with psychological distress in the Spanish adult population. Addictive Behaviors, 2015, 50, 84-88.	3.0	15
128	Assessment of cannabis use disorders: a systematic review of screening and diagnostic instruments. Psychological Medicine, 2015, 45, 1121-1133.	4.5	39
129	Alcohol dependence and treatment utilization in Europe – a representative cross-sectional study in primary care. BMC Family Practice, 2015, 16, 90.	2.9	93
130	Who receives treatment for alcohol use disorders in the European Union? A cross-sectional representative study in primary and specialized health care. European Psychiatry, 2015, 30, 885-893.	0.2	40
131	New perspectives for the treatment of alcoholism. Medicina ClÃnica (English Edition), 2015, 144, 24-25.	0.2	0
132	Maintenance of tobacco cessation programmes in public hospitals in Catalonia, Spain. Addictive Behaviors, 2015, 42, 136-139.	3.0	8
133	Prevalence of and Potential Influencing Factors for Alcohol Dependence in Europe. European Addiction Research, 2015, 21, 6-18.	2.4	141
134	Evaluaci $ ilde{A}^3$ n del consumo de riesgo de alcohol en estudiantes universitarios de la Facultad de Farmacia. Revista De Psicologia De La Salud, 2015, 27, 190.	0.5	9
135	Wim van den Brink and colleagues reply to Des Spence and Alain Braillon. BMJ, The, 2014, 348, g2605-g2605.	6.0	4
136	Motivational Interviewing for Smoking Cessation in a Psychiatric Day Hospital: A Feasibility Study. Journal of Dual Diagnosis, 2014, 10, 226-229.	1.2	0
137	Managing Alcohol Problems in General Practice in Europe: Results from the European ODHIN Survey of General Practitioners. Alcohol and Alcoholism, 2014, 49, 531-539.	1.6	61
138	The Tangible Common Denominator of Substance Use Disorders: A Reply to Commentaries to Rehm et al. (2013a). Alcohol and Alcoholism, 2014, 49, 118-122.	1.6	49
139	Wernicke-Korsakoff's Syndrome: Waiting for Godot?. Alcohol and Alcoholism, 2014, 49, 117-118.	1.6	4
140	Can Alcohol Dependent Patients Adhere to an â€~As-Needed' Medication Regimen?. European Addiction Research, 2014, 20, 209-217.	2.4	19
141	Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study. Journal of Psychopharmacology, 2014, 28, 733-744.	4.0	109
142	The Relationships Between the Impact of Alcoholic Beverage Control Policies, Selected Contextual Determinants, and Alcohol Drinking in Spain. Substance Use and Misuse, 2014, 49, 1665-1683.	1.4	7
143	A randomised controlled non-inferiority trial of primary care-based facilitated access to an alcohol reduction website (EFAR Spain): the study protocol. BMJ Open, 2014, 4, e007130.	1.9	21
144	Implementing training and support, financial reimbursement, and referral to an internet-based brief advice program to improve the early identification of hazardous and harmful alcohol consumption in primary care (ODHIN): study protocol for a cluster randomized factorial trial. Implementation Science, 2013, 8, 11.	6.9	44

#	Article	IF	CITATIONS
145	Extending the Treatment Options in Alcohol Dependence: A Randomized Controlled Study of As-Needed Nalmefene. Biological Psychiatry, 2013, 73, 706-713.	1.3	457
146	Attitudes and managing alcohol problems in general practice in Europe: results from the European ODHIN study. Addiction Science & European Results of Scienc	2.6	0
147	The ODHIN assessment tool: a tool to describe the available services for the management of hazardous and harmful alcohol consumption at the country and regional level. Addiction Science & Eamp; Clinical Practice, 2013, 8, .	2.6	0
148	Defining Substance Use Disorders: Do We Really Need More Than Heavy Use?. Alcohol and Alcoholism, 2013, 48, 633-640.	1.6	193
149	A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. European Neuropsychopharmacology, 2013, 23, 1432-1442.	0.7	359
150	Efficacy of As-Needed Nalmefene in Alcohol-Dependent Patients with at Least a High Drinking Risk Level: Results from a Subgroup Analysis of Two Randomized Controlled 6-Month Studies. Alcohol and Alcoholism, 2013, 48, 570-578.	1.6	293
151	Second-hand smoke in mental healthcare settings: time to implement total smoke-free bans?. International Journal of Epidemiology, 2013, 42, 886-893.	1.9	16
152	Gender differences in the longâ€ŧerm outcome of alcohol dependence treatments: An analysis of twentyâ€year prospective follow up. Drug and Alcohol Review, 2013, 32, 381-388.	2.1	22
153	Consumo de alcohol, dependencia alcoh $\tilde{A}^3$ lica, trastornos relacionados con el alcohol en Espa $\tilde{A}\pm a$ . Impacto de los tratamientos de la dependencia alcoh $\tilde{A}^3$ lica. Revista De Psicologia De La Salud, 2013, 25, 11.	0.5	26
154	Reduction of Alcohol Consumption and Subsequent Mortality in Alcohol Use Disorders. Journal of Clinical Psychiatry, 2013, 74, e1181-e1189.	2.2	77
155	Alcohol dependence treatment in the EU: A literature search and expert consultation about the availability and use of guidelines in all EU countries plus Iceland, Norway, and Switzerland. The International Journal of Alcohol and Drug Research, 2013, 2, 53-67.	0.9	22
156	The International Diffusion Of European Alcohol Research / Mednarodna Razpršenost Evropskih Raziskav O Alkoholu. Zdravstveno Varstvo, 2013, 52, 19-26.	0.9	0
157	Alcohol consumption, alcohol dependence and related harms in Spain, and the effect of treatment-based interventions on alcohol dependence. Revista De Psicologia De La Salud, 2013, 25, 11-8.	0.5	7
158	Smoke-free policies in psychiatric services: identification of unmet needs. Tobacco Control, 2012, 21, 549-554.	3.2	13
159	Predictive factors of abstinence in patients undergoing liver transplantation for alcoholic liver disease. Annals of Hepatology, 2012, 11, 213-221.	1.5	28
160	Predictive factors of abstinence in patients undergoing liver transplantation for alcoholic liver disease. Annals of Hepatology, 2012, 11, 213-21.	1.5	4
161	Simultaneous versus Delayed Treatment of Tobacco Dependence in Alcohol-Dependent Outpatients. European Addiction Research, 2011, 17, 1-9.	2.4	26
162	The alternative five-factor model of personality, nicotine dependence and relapse after treatment for smoking cessation. Addictive Behaviors, 2011, 36, 965-971.	3.0	25

#	Article	IF	CITATIONS
163	Implementing alcohol disorders treatment throughout the community. Current Opinion in Psychiatry, 2011, 24, 203-207.	6.3	9
164	Identifying the gap between need and intervention for alcohol use disorders in Europe. Addiction, 2011, 106, 31-36.	3.3	36
165	A new AMPHORA: an introduction to the project Alcohol Measures for Public Health Research Alliance. Addiction, 2011, 106, 1-3.	3.3	7
166	Reflections on science and the governance of alcohol policy. Addiction, 2011, 106, 67-70.	3.3	2
167	RISKY SINGLE DRINKING OCCASIONS OR ACUTE ALCOHOL INTOXICATIONS?. Addiction, 2011, 106, 1048-1049.	3.3	2
168	Patterns of substance use in adolescents attending a mental health department. European Child and Adolescent Psychiatry, 2011, 20, 279-289.	4.7	17
169	Contextual Determinants of Alcohol Consumption Changes and Preventive Alcohol Policies: A 12-Country European Study in Progress. Substance Use and Misuse, 2011, 46, 1288-1303.	1.4	45
170	Brief intervention in substance-use among adolescent psychiatric patients: a randomized controlled trial. European Child and Adolescent Psychiatry, 2010, 19, 503-511.	4.7	24
171	CONFLICTS OF INTEREST. A GOLDEN STANDARD TO GENERALIZE IN ADDICTION RESEARCH. Addiction, 2010, 105, 199-200.	3.3	2
172	Prevalence and Factors Related to Substance Use among Adolescents with Eating Disorders. European Addiction Research, 2010, 16, 61-68.	2.4	23
173	The research translation problem: Alcohol screening and brief intervention in primary care – Real world evidence supports theory. Drugs: Education, Prevention and Policy, 2010, 17, 732-748.	1.3	24
174	A case of double exclusion. European Journal of Public Health, 2010, 20, 618-618.	0.3	0
175	Treatment for Alcohol Dependence in Catalonia: Health Outcomes and Stability of Drinking Patterns over 20 Years in 850 Patients. Alcohol and Alcoholism, 2009, 44, 409-415.	1.6	45
176	Impaired theta phase-resetting underlying auditory N1 suppression in chronic alcoholism. NeuroReport, 2009, 20, 337-342.	1.2	6
177	Children of alcoholics in Spain: from risk to pathology. Social Psychiatry and Psychiatric Epidemiology, 2008, 43, 1-10.	3.1	45
178	TRANSLATIONAL RESEARCH: A NECESSARY AND DIFFICULT STEP FORWARD IN THE ADDICTIONS FIELD. Addiction, 2008, 103, 1065-1066.	3.3	3
179	Clinical and research utility of Spanish Teen-Addiction Severity Index (T-ASI). Addictive Behaviors, 2008, 33, 188-195.	3.0	15
180	Dual diagnosis in inpatient physicians: prevalence and clinical characteristics. Mental Health and Substance Use: Dual Diagnosis, 2008, 1, 10-20.	0.5	10

#	Article	IF	Citations
181	Clinical approach to intestinal maturation in neonates prenatally exposed to alcohol. Alcohol and Alcoholism, 2007, 42, 407-412.	1.6	7
182	Dual diagnosis in Spain. Drug and Alcohol Review, 2007, 26, 65-71.	2.1	30
183	IS ALCOHOL FOODSTUFF?. Addiction, 2007, 102, 1190-1191.	3.3	3
184	Alcohol in Spain: is it different?. Addiction, 2006, 101, 1073-1077.	3.3	28
185	A multicountry controlled trial of strategies to promote dissemination and implementation of brief alcohol intervention in primary health care: findings of a World Health Organization collaborative study Journal of Studies on Alcohol and Drugs, 2005, 66, 379-388.	2.3	95
186	Prevalence and Mechanisms of Hyperhomocysteinemia in Chronic Alcoholics. Alcoholism: Clinical and Experimental Research, 2005, 29, 1044-1048.	2.4	54
187	ATTITUDES AND MANAGING ALCOHOL PROBLEMS IN GENERAL PRACTICE: AN INTERACTION ANALYSIS BASED ON FINDINGS FROM A WHO COLLABORATIVE STUDY. Alcohol and Alcoholism, 2004, 39, 351-356.	1.6	114
188	Electrophysiological evidence of abnormal activation of the cerebral network of involuntary attention in alcoholism. Clinical Neurophysiology, 2003, 114, 134-146.	1.5	53
189	SERTRALINE FOR THE PREVENTION OF RELAPSE IN DETOXICATED ALCOHOL DEPENDENT PATIENTS WITH A COMORBID DEPRESSIVE DISORDER: A RANDOMIZED CONTROLLED TRIAL. Alcohol and Alcoholism, 2003, 38, 619-625.	1.6	37
190	AUDIT-3 AND AUDIT-4: EFFECTIVENESS OF TWO SHORT FORMS OF THE ALCOHOL USE DISORDERS IDENTIFICATION TEST. Alcohol and Alcoholism, 2002, 37, 591-596.	1.6	258
191	A Double-Blind, Placebo-Controlled Study of Naltrexone in the Treatment of Alcohol-Dependence Disorder: Results from a Multicenter Clinical Trial. Alcoholism: Clinical and Experimental Research, 2002, 26, 1381-1387.	2.4	100
192	A Double-Blind, Placebo-Controlled Study of Naltrexone in the Treatment of Alcohol-Dependence Disorder: Results from a Multicenter Clinical Trial. Alcoholism: Clinical and Experimental Research, 2002, 26, 1381-1387.	2.4	2
193	A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Alcoholism: Clinical and Experimental Research, 2002, 26, 1381-7.	2.4	54
194	Auditory sensory memory as indicated by mismatch negativity in chronic alcoholism. Clinical Neurophysiology, 2001, 112, 728-731.	1.5	32
195	From Paris to Stockholm: where does the European Alcohol Action Plan lead to?. Addiction, 2001, 96, 1093-1096.	3.3	4
196	Attrition in group therapy with alcoholics: a survival analysis. Drug and Alcohol Review, 2000, 19, 55-63.	2.1	13
197	Mismatch Negativity and Auditory Sensory Memory in Chronic Alcoholics. Alcoholism: Clinical and Experimental Research, 1999, 23, 1744-1750.	2.4	26
198	Why has alcohol consumption declined in countries of southern Europe?. Addiction, 1997, 92, S21-S31.	3.3	77

## Antoni Gual

#	Article	IF	CITATIONS
199	Scaling-up primary health care-based prevention and management of alcohol use disorder at the municipal level in middle-income countries in Latin America: Background and pre-protocol for a three-country quasi-experimental study. F1000Research, 0, 6, 311.	1.6	2
200	The iCannTookit: A consensusâ€based, flexible framework for measuring contemporary cannabis use. Addiction, 0, , .	3.3	1